ARCS-M: forging progress from this negative trial in malignant pleural mesothelioma

Lancet Oncol. 2022 Apr;23(4):445-446. doi: 10.1016/S1470-2045(22)00099-7.

Authors

Marjorie G Zauderer¹, Michael Offin²

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY 10021, USA. Electronic address: zauderem@mskcc.org.
² Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY 10021, USA.

PMID: 35358447
DOI: 10.1016/S1470-2045(22)00099-7

No abstract available

Publication types

Clinical Trial
Comment

MeSH terms

Humans
Mesothelioma* / pathology
Mesothelioma* / therapy
Mesothelioma, Malignant*
Pleural Neoplasms* / pathology
Pleural Neoplasms* / therapy